دورية أكاديمية
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma
| العنوان: | Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma |
|---|---|
| المؤلفون: | Odia, Yazmin, Koschmann, Carl, Vitanza, Nicholas A, de Blank, Peter, Aguilera, Dolly, Allen, Jeffrey, Daghistani, Doured, Hall, Matthew, Khatib, Ziad, Kline, Cassie, MacDonald, Tobey, Mueller, Sabine, Faison, Shamia L, Allen, Joshua E, Naderer, Odin J, Ramage, Samuel C, Tarapore, Rohinton S, McGovern, Susan Lynne, Khatua, Soumen, Zaky, Wafik, Gardner, Sharon L |
| المساهمون: | Chimerix, Making Headway Foundation |
| المصدر: | Neuro-Oncology ; volume 26, issue Supplement_2, page S155-S164 ; ISSN 1522-8517 1523-5866 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| الوصف: | Background This study evaluated the safety and pharmacokinetics (PK) of oral ONC201 administered twice-weekly on consecutive days (D1D2) in pediatric patients with newly diagnosed DIPG and/or recurrent/refractory H3 K27M glioma. Methods This phase 1 dose-escalation and expansion study included pediatric patients with H3 K27M-mutant glioma and/or DIPG following ≥1 line of therapy (NCT03416530). ONC201 was administered D1D2 at 3 dose levels (DLs; −1, 1, and 2). The actual administered dose within DLs was dependent on weight. Safety was assessed in all DLs; PK analysis was conducted in DL2. Patients receiving once-weekly ONC201 (D1) served as a PK comparator. Results Twelve patients received D1D2 ONC201 (DL1, n = 3; DL1, n = 3; DL2, n = 6); no dose-limiting toxicities or grade ≥3 treatment-related adverse events occurred. PK analyses at DL2 (D1-250 mg, n = 3; D1-625 mg, n = 3; D1D2-250 mg, n = 2; D1D2-625 mg, n = 2) demonstrated variability in Cmax, AUC0–24, and AUC0–48, with comparable exposures across weight groups. No accumulation occurred with D1D2 dosing; the majority of ONC201 cleared before administration of the second dose. Cmax was variable between groups but did not appear to increase with D1D2 dosing. AUC0–48 was greater with D1D2 than once-weekly. Conclusions ONC201 given D1D2 was well tolerated at all DLs and associated with greater AUC0–48. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/neuonc/noae001 |
| DOI: | 10.1093/neuonc/noae001/56751870/noae001.pdf |
| الإتاحة: | https://doi.org/10.1093/neuonc/noae001Test https://academic.oup.com/neuro-oncology/article-pdf/26/Supplement_2/S155/57370270/noae001.pdfTest |
| حقوق: | https://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: | edsbas.C5BAA034 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/neuonc/noae001 |
|---|